Status:
UNKNOWN
Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV
Lead Sponsor:
University of Sao Paulo General Hospital
Conditions:
Cytomegalovirus Infections
CMV
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation. Patients studied are those already infected by CMV...
Detailed Description
This study evaluates Quantiferon-CMV assay ability for CMV (cytomegalovirus) risk prediction in kidney transplant recipients. Quantiferon-Monitor ability to predict infection or graft rejection will b...
Eligibility Criteria
Inclusion
- CMV IgG seropositivity before kidney transplant
- to provide signed Informed Consent
Exclusion
- death or graft failure before day 19 post-transplant
- allergy to valganciclovir ou ganciclovir
Key Trial Info
Start Date :
August 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03858907
Start Date
August 5 2018
End Date
November 30 2020
Last Update
March 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clinicas, University of Sao Paulo School of MedicinE
São Paulo, São Paulo, Brazil, 05403-900